CHMP Recommends Lilly’s Oral GLP-1 Foundayo

Europe's path to a second oral GLP-1 just got shorter. On 15 October 2026, at its 12–15 October plenary, the EU's Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorisation for Eli Lilly's Foundayo (orforglipron) — an oral, once-daily small-molecule GLP-1 receptor agonist — for both weight management and type 2 diabetes in adults. It is the first oral GLP-1 opinion in the EU to cover both uses under one filing, and a broader scope than the UK's own authorisation of the same drug in August.

What CHMP actually decided

A CHMP opinion is not a marketing authorisation. It is the EU's scientific committee — the body responsible for preparing EMA's opinions on all questions concerning human medicines — recommending that the European Commission grant one. For Foundayo, the recommendation spans two indications in a single filing: adult weight management, and treatment of type 2 diabetes, either as monotherapy when metformin is unsuitable or in combination with other glucose-lowering therapies. Combining both uses in one opinion is itself notable; Novo Nordisk's oral semaglutide tablet reached a positive EU opinion in July 2026 for weight management only, making Foundayo the first oral GLP-1 opinion in Europe to carry a dual scope from the outset. It is also a wider scope than Foundayo's own first European clearance: the UK's MHRA authorised it on 10 August 2026, for weight management alone, as the first regulator in Europe to approve the drug at all. This CHMP opinion is the EU-wide follow-on, covering 27 member states at once and adding the diabetes indication the UK approval did not include — a separate regulatory action, not a restatement of the UK one.

Why oral, small-molecule matters operationally

Orforglipron is a small-molecule GLP-1 receptor agonist taken as a once-daily tablet, not an injectable peptide. That distinction carries real regulatory and supply-chain weight: no prefilled syringe or autoinjector human-factors package, no cold-chain distribution, and — per the reporting reviewed for this story — none of the food-or-water timing restrictions that accompany some oral peptide GLP-1 formulations. For sponsors and manufacturing teams tracking the GLP-1 class, it is a second data point (after Novo's oral tablet) that regulators will evaluate small-molecule oral GLP-1s on the same efficacy bar as the injectables, without requiring the device-related submissions that come with a self-injection system.

The evidence CHMP reviewed

• Weight management: 72-week trials showed weight loss of approximately 5–11% depending on dose, against roughly 2–2.5% with placebo.
• Type 2 diabetes: across four studies totalling approximately 3,765 adults, HbA1c fell by roughly 1.2–1.9 percentage points versus placebo, with the indication covering both monotherapy (when metformin is inappropriate) and combination use.
• Safety: the most commonly reported adverse effects were nausea, vomiting and diarrhoea, concentrated during dose escalation — consistent with the GLP-1 class generally.

What is not yet settled

A CHMP opinion is not the end of the process. It now goes to the European Commission, which issues the binding decision on an EU-wide marketing authorisation; Commission decisions typically follow a positive opinion within about two months, though EMA has not published a specific date for this one. Pricing and reimbursement are not decided at the EU level at all — each member state negotiates those terms separately after authorisation, meaning the opinion sets the clinical and regulatory scope but says nothing about when, or at what cost, Foundayo actually reaches patients in any given country.

Frequently asked questions

What did CHMP recommend, and when?

A positive opinion for Foundayo (orforglipron), from Eli Lilly Nederland B.V., adopted 15 October 2026 at the committee's 12–15 October plenary and published in EMA's meeting highlights 16 October 2026.

What is orforglipron, and what is it for?

An oral, once-daily, small-molecule GLP-1 receptor agonist. The opinion covers adult weight management and treatment of type 2 diabetes, as monotherapy when metformin is inappropriate or in combination with other glucose-lowering medicines.

What is the evidence behind the opinion?

72-week weight loss of roughly 5–11% depending on dose versus 2–2.5% with placebo; across four diabetes studies (~3,765 adults), HbA1c fell about 1.2–1.9 points versus placebo. Most common side effects: nausea, vomiting, diarrhoea, mainly during dose escalation.

What happens next?

The European Commission issues the binding EU-wide authorisation decision, typically within about two months of a positive opinion. Pricing and reimbursement are then set separately by each member state.